HMN Posts Q3 as Options Traders Turn Bullish and Insiders Keep Selling

HMN heads into its Q3 results with an unusual split: options positioning has shifted more bullish than it has been in months, while insiders have spent the past quarter selling at every opportunity, including one more tranche from the CEO on the day before the report.

The clearest shift this week is in the options market, where sentiment has moved notably more constructive. The put/call ratio has dropped to 0.65, more than a standard deviation below its 20-day average of 0.77, reaching its lowest reading since late September when the ratio briefly dipped toward 0.14 on what appears to have been thin volume. That compares with a 52-week high of 1.32 hit in late September, when protection demand spiked. The current tilt toward calls suggests investors are positioning for upside around the print rather than hedging against a miss. Short interest provides little drama: at 2.5% of the free float, with a borrow cost of 0.53% and availability running at roughly 7,466%, the lending market is entirely unencumbered. Shares available to borrow dwarf those actually borrowed by a factor of around 75 to one. There is no squeeze pressure here, and the short score of 34.3 sits in the bottom half of the universe, consistent with a stock most investors are not actively fighting.

The Street's view on HMN is mixed but tilted positive, with the most recent analyst data from mid-2025 reflecting a spread of opinions. The last notable action was BMO Capital's initiation at Outperform with a $48 target in July 2025, while Piper Sandler and KBW have both maintained more cautious stances at Neutral and Market Perform respectively. Raymond James holds a Strong Buy. The consensus mean target from that period sat at $56.50, though at today's price of $47.47 that implies meaningful upside on paper. Investors should note the analyst data is now roughly 15 months old; the Street has been quiet on HMN since mid-2025 and those targets may no longer reflect current views. Valuation looks undemanding on current figures: the stock trades at a P/E of 9.5 and 1.09 times book, both modest for a profitable insurer. The earnings yield ranks in the 62nd percentile, and the EPS surprise factor score of 85 suggests the company has a consistent track record of beating estimates, a relevant datapoint the night before a print. The bull case centres on improving margins in the property-casualty and supplemental benefits segments, plus 25% year-on-year growth in worksite direct distribution. Bears point to the company's niche concentration in the educator market as a structural growth ceiling.

The insider picture has not changed since the previous note filed earlier today: net sales of $1.69 million over the past 90 days, with no purchases recorded. CEO Marita Zuraitis executed another 7,500-share sale on November 2, the day before the earnings report, at $47.20 and under her 10b5-1 plan. That plan removes much of the conviction signal. The more noteworthy sales remain the discretionary ones: director Perry Hines sold $169,000 on September 3, General Counsel Donald Carley sold $107,000 the same day, and director Thomas Bradley sold $258,000 in mid-August, all three outside any pre-arranged plan and all executed when the stock was trading above $50. The stock has since pulled back roughly 7% from those levels. On the ownership side, the register is concentrated in passive and quasi-passive hands: BlackRock holds 14.5%, with Vanguard entities, Franklin Templeton, and T. Rowe Price collectively accounting for another 25% or so. Wasatch Advisors added 562,567 shares in Q3 and American Century added 271,569, the two most material new positions among the top holders. No 13D activist is on the register.

The only prior comparable earnings reaction in the data covers Q2 results in August, when the stock moved just 0.23% on the day but drifted 0.42% lower over the following five sessions, suggesting modest post-earnings drift rather than sharp moves in either direction.

What to watch now is whether Q3 results, expected November 5, confirm the margin improvement thesis or reveal a reversion, and whether the options market's tilt toward calls proves well-placed or simply reflects light put activity ahead of what has historically been a quiet earnings event.